Want to see TAK full AI Analyst Report?
Takeda Pharmaceutical Company (TAK) Income Statement
Takeda Pharmaceutical Company Income Statement
Last quarter (Q2 2026), Takeda Pharmaceutical Company's total revenue was $1.19T, an increase of 6.68% from the same quarter last year. In Q2, Takeda Pharmaceutical Company's net income was $192.43B. See Takeda Pharmaceutical Company’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| $ 4.78T | $ 4.58T | $ 4.26T | $ 4.03T | $ 3.57T | |
| $ 2.44T | $ 3.00T | $ 2.83T | $ 2.78T | $ 2.46T | |
| $ 1.87T | $ 2.66T | $ 2.62T | $ 2.29T | $ 2.00T | |
| Depreciation and Amortization | $ 721.13B | $ 761.40B | $ 728.00B | $ 664.40B | $ 583.15B |
| $ 1.38T | $ 1.21T | $ 1.23T | $ 1.28T | $ 1.18T | |
| $ 573.04B | $ 342.59B | $ 214.07B | $ 490.50B | $ 460.84B | |
| $ -297.16B | $ -167.50B | $ -161.28B | $ -115.42B | $ -158.27B | |
| $ 275.88B | $ 175.08B | $ 52.79B | $ 375.09B | $ 302.57B | |
| $ 203.33B | $ 107.93B | $ 144.07B | $ 317.02B | $ 230.06B | |
| Per Share Metrics | |||||
| Basic EPS | $ 63.91 | $ 34.17 | $ 46.05 | $ 102.15 | $ 73.57 |
| Diluted EPS | $ 63.91 | $ 33.62 | $ 45.58 | $ 100.97 | $ 72.94 |
| Weighted Average Shares Outstanding | 3.15B | 3.21B | 3.13B | 3.10B | 3.13B |
| Weighted Average Shares Outstanding (Diluted) | 3.21B | 3.21B | 3.16B | 3.14B | 3.15B |
Currency in JPY